MetaCap

LB Pharmaceuticals (LBRX) vs Mineralys Therapeutics (MLYS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

LB Pharmaceuticals (LBRX) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 153.4% versus a loss of 67.4%. LB Pharmaceuticals is the larger company by market cap ($1.26 billion vs $1.21 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LBRX+153.42%MLYS-67.38%
+237%+78%-82%
Nov 21, 20251 yearNov 20, 2026
LBRX+131.25%MLYS-63.18%
+207%+65%-76%
Sep 8, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LBRX versus MLYS key metrics
MetricLBRXMLYS
Share price$38.85$13.66
Market cap$1.26B$1.21B
1-day change-2.97%-3.53%
YTD return+74.53%-62.36%
1-year return+153.42%-67.38%
EPS (TTM)$-1.12$-4.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-25.20M$-154.65M
52-week high$50.16$44.13
52-week low$15.55$13.57
Distance from 52-week high-22.55%-69.05%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+49.29%+218.89%
Average volume373.16K1.55M
Shares outstanding32.36M88.56M
Employees6276
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LBRX has outperformed MLYS by 220.8 percentage points over the past year.

About LB Pharmaceuticals

LBRX stock →

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.

Health Care · Biotechnology: Pharmaceutical Preparations · 62 employees

About Mineralys Therapeutics

MLYS stock →

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

LBRX vs MLYS FAQ

Which is bigger, LB Pharmaceuticals or Mineralys Therapeutics?

LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.26B compared with $1.21B for Mineralys Therapeutics (MLYS).

Which stock has performed better over the past year, LBRX or MLYS?

LBRX returned +153.42% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.

Are LB Pharmaceuticals and Mineralys Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons